Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

46+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 66 running projects, newest first. Listed amounts together: 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Frissítve: 2026. nov. 6.

  “Business reasons and not based on any safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Frissítve: 2026. okt. 23.

  “Company's strategic decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT05358249· Novartis Pharmaceuticals· Frissítve: 2026. okt. 21.

  “Business reasons and not based on any safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Incyte Corporation· Frissítve: 2026. szept. 8.

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

  NCT06333678· Memorial Sloan Kettering Cancer Center· Frissítve: 2026. szept. 2.

  “Study closed by Amgen due to lack of enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

  NCT07639242· UNC Lineberger Comprehensive Cancer Center· Frissítve: 2026. aug. 28.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· BeOne Medicines· Frissítve: 2026. júl. 8.

  “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

  NCT06704724· Pfizer· Frissítve: 2026. máj. 22.

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Frissítve: 2026. ápr. 9.

  “Sponsor discontinued the trial”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Frissítve: 2026. febr. 19.

  “business objectives have changed”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Merck Sharp & Dohme LLC· Forrás

• MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Merck Sharp & Dohme LLC· Forrás

• A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Merck Sharp & Dohme LLC· Forrás

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Merck Sharp & Dohme LLC· Forrás

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· Merck Sharp & Dohme LLC· Forrás

• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· AstraZeneca· Forrás

• A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Astellas Pharma Global Development, Inc.· Forrás

• A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Hoffmann-La Roche· Forrás

• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Forrás

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Amgen· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• [Drug sensitivity analysis of monotherapy and combination therapy with Chinese and Western drugs in lung cancer organoid models].

  Zhonghua Zhong Liu Za Zhi, 2026. okt.

• CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.

  Biochem Biophys Res Commun, 2026. szept.

• Single-cell lineage tracing in tumor organoids identifies expansion states depicting the origin and progression of lung adenocarcinoma.

  Front Immunol, 2026. szept.

• Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence.

  Int J Mol Sci, 2026. szept.

• The neuro-immune-vascular landscape of lung cancer brain metastasis: insights from organoid models.

  Front Immunol, 2026. aug.

• Proof-of-concept study in patient-derived organoids from malignant pleural effusion for functional testing in thoracic tumors.

  Biomed Pharmacother, 2026. aug.

• Lung organoids and organ-on-a-chip models in respiratory disease research: advances, applications, and challenges.

  Respir Res, 2026. júl.

• Development and clinical application of a primary cancer organoid-PBMC co-culture system for personalized immunotherapy.

  Drug Resist Updat, 2026. júl.

• [Standardized Construction of Lung Cancer Organoids and Their Application Progress in the Precise Treatment of Lung Cancer].

  Zhongguo Fei Ai Za Zhi, 2026. jún.

• Patient-specific lung cancer tumoroids recapitulate the tumor microenvironments for functional evaluation of therapeutic responses and immune-stromal interactions.

  J Transl Med, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.